BidaskClub Downgrades Shire (SHPG) to Strong Sell

Shire (NASDAQ:SHPG) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Friday.

A number of other research firms also recently weighed in on SHPG. Piper Jaffray Companies restated a “hold” rating on shares of Shire in a research report on Wednesday, January 3rd. Cantor Fitzgerald set a $222.00 target price on Shire and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Liberum Capital restated a “hold” rating on shares of Shire in a research report on Wednesday, December 20th. Cowen set a $225.00 target price on Shire and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, Royal Bank of Canada restated a “buy” rating and issued a $213.00 target price on shares of Shire in a research report on Monday, October 2nd. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $212.18.

Shire (SHPG) traded up $2.98 during trading hours on Friday, reaching $147.55. The company had a trading volume of 2,849,528 shares, compared to its average volume of 1,350,000. The company has a market cap of $45,240.00, a P/E ratio of 27.79, a price-to-earnings-growth ratio of 0.78 and a beta of 1.59. Shire has a one year low of $137.17 and a one year high of $192.15. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55.

Shire (NASDAQ:SHPG) last released its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.64 by $0.17. The company had revenue of $3.70 billion during the quarter. Shire had a return on equity of 14.41% and a net margin of 10.95%. The business’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.17 EPS. research analysts anticipate that Shire will post 15.01 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the business. Perkins Capital Management Inc. bought a new stake in Shire in the fourth quarter valued at approximately $516,000. Commerzbank Aktiengesellschaft FI lifted its position in Shire by 22.1% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 2,073 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 375 shares during the last quarter. FNY Partners Fund LP lifted its position in Shire by 346.6% in the fourth quarter. FNY Partners Fund LP now owns 474,460 shares of the biopharmaceutical company’s stock valued at $73,598,000 after purchasing an additional 368,214 shares during the last quarter. SG Americas Securities LLC lifted its position in Shire by 31.5% in the fourth quarter. SG Americas Securities LLC now owns 8,630 shares of the biopharmaceutical company’s stock valued at $1,339,000 after purchasing an additional 2,068 shares during the last quarter. Finally, Selz Capital LLC lifted its position in Shire by 19.1% in the fourth quarter. Selz Capital LLC now owns 107,400 shares of the biopharmaceutical company’s stock valued at $16,660,000 after purchasing an additional 17,200 shares during the last quarter. Hedge funds and other institutional investors own 20.24% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was published by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/27/bidaskclub-downgrades-shire-shpg-to-strong-sell.html.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply